bioLytical

bioLytical Laboratories Inc. is a Canadian company based in Richmond, British Columbia, established in 2002. It specializes in developing and manufacturing rapid in vitro diagnostic tests, primarily for infectious diseases such as HIV, hepatitis B, and hepatitis C. The company is recognized for its INSTI® HIV rapid test, which was first introduced in Canada and the European Union in 2006 and later in the US in 2010. bioLytical was the first in Canada to receive approval for an HIV self-test, which has been widely utilized in large-scale self-testing programs in Sub-Saharan Africa. All of bioLytical's products are developed in-house and manufactured locally in Canada, ensuring quality and reducing supply chain risks. Their offerings include rapid HIV tests for point-of-care and self-testing, as well as ongoing development of hepatitis B and C tests. The company serves a diverse range of customers, including healthcare providers and international health organizations, with a focus on improving global health outcomes through early diagnosis and self-testing options.

• Employees 95
• Founded 2002
• Annual Revenue $40000000